Published by Coherent Market Insights
Posted on September 15, 2021
3 min readLast updated: February 10, 2026
Add as preferred source on Google
Global Immune Repertoire Sequencing Market, By Product Type (Instruments and Assay Kits (B-Cell Receptor Kits and T-Cell Receptor Kits)), By Application (Infectious Diseases, Cancer Immunotherapy, Vaccine Development & Efficacy, Autoimmune Diseases, Biomarker Discovery, and Transplant Rejection & Tolerance), By End User (Academic & Research Institutes, Diagnostic Labs, and Pharmaceutical & Biotechnology Companies), and By Geography (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa), is projected to attain a market valuation of US$ XX million in 2021 and is anticipated to grow at a CAGR of XX% during the forecast period (2021-2028), as mentioned in a new report published by Coherent Market Insights.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1517
Overview
The promising methodology for analyzing human immune repertoire is DNA fingerprinting. The method is based on tandem duplication of DNA molecules between highly informative probes that directly capture the genetic variation. Multiple measurements of such parameters as heterozygosis, homozygosis, frequency of tandem duplication, and others are used to determine genetic differences among humans. This method relies on highly sensitive and molecular probes such as cytogenetics, transcriptomics, RSN typing and others. The results are comparable with those of whole genome sequencing methods. Moreover, this technique can be used to study the complex genetic interactions between humans.
Competitive Landscape
Major companies contributing in the global immune repertoire sequencing market include Thermo Fisher Scientific, Roche Holding, CD Genomics, Junom Therapeutics, ArcherDX, Adaptive Biotechnologies, Atreca, Illumina, and Pacific Biosciences.
Drivers
Growing penetration of advanced immune repertoire sequencing methodology in personalized immune alteration procedures is expected to propel growth of the immune repertoire sequencing market during the forecast period.
Moreover, increasing application of immune repertoire sequencing in the treatment of cancer, allergies, biomarkers development, and others combined with the increased volume of product launches is expected to augment growth of the immune repertoire sequencing market throughout the forecast period.
The Epitome of the COVID-19 Aftermath
The global immune repertoire sequencing market has witnessed moderate growth due to the ongoing COVID-19 prevalence. The one-year, ten-month old virus has raised the demand and awareness among people over the significance of immunity-boosters. The infected people suffered from weakness in their immune systems, thus, catalyzing the demand for immunotherapies.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1517
Key Takeaways
The immune repertoire sequencing market is anticipated to grow at a CAGR of XX % during the forecast period owing to the advent of advanced sequencing methods and increasing number of product launches. For instance, in August 2021, the Centers for Commercialization of Cancer Immunotherapy (C3i) report that immunotherapies will account for 60% of overall cancer treatments by 2025.
From the geographical standpoint, the North American region is poised to accelerate the expansion of the immune repertoire sequencing market on the heels of increased adoption of immunotherapy in treating infectious diseases and cancer.
Another noteworthy geographic region is Europe, which is catalyzed by increasing expenditure of R&D activities aimed at developing immune repertoire sequencing solutions.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1517
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Immune Repertoire Sequencing Market Size to Increase by US$ 114.3 million during 2018-2026 | Forecasting Strategies appeared first on Gatorledger.
The immune repertoire sequencing market is anticipated to grow by US$ 114.3 million during the forecast period from 2018 to 2026.
Key drivers include the increasing application of immune repertoire sequencing in cancer treatment and personalized medicine, as well as advancements in sequencing methods.
North America is expected to lead the market expansion due to higher adoption of immunotherapy, while Europe is also notable for its increased R&D expenditures.
Major companies include Thermo Fisher Scientific, Roche Holding, CD Genomics, and Adaptive Biotechnologies, among others.
The ongoing COVID-19 pandemic has raised awareness and demand for immune repertoire sequencing, contributing to moderate growth in the market.
Explore more articles in the Research Reports category
